Semaglutide 2·[amount hidden] once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

Who Took Part

The study group was 3, adults.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Patients were recruited from 149 outpatient clinics in 12 countries across Europe, North America, South America, the Middle East, South Africa, and Asia.

Patients, investigators, and those assessing outcomes were masked to group assignment.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

This study is registered with ClinicalTrials.gov, NCT03552757 and is closed to new participants.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents, Obesity, Overweight and Weight Loss.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 3, adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Lancet (London, England)), a journal based in England.

More context: the Semaglutide compound page.